Cochrane reviewer sues Roche for claiming Tamiflu could slow flu pandemic
BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m314 (Published 27 January 2020)Cite this as: BMJ 2020;368:m314
- Owen Dyer
A UK epidemiologist and Cochrane Collaboration researcher is suing the drug company Roche in the US, claiming that it defrauded federal and state governments by falsely claiming that its antiviral drug oseltamivir (Tamiflu) could be a powerful tool in mitigating a flu pandemic.
Tom Jefferson, a frequent contributor to The BMJ, is suing as a private whistleblower for $1.5bn (£1.1bn; €1.4bn), roughly the amount that US public health authorities spent building up their pandemic stockpile of oseltamivir. The stockpile is still maintained today, though recent purchases have involved generic versions, as Tamiflu’s main patent expired in 2016.
Should Jefferson win, he would be awarded up to 30% of any monies recovered, while the rest would be returned to public coffers. (See link for article)
“Tamiflu can cause significant adverse effects in patients. I brought this suit because I felt so many, including the US government, have been misled by what I allege in the complaint are false statements about Tamiflu’s efficacy for pandemic use.”
Many falsely believe anti-virals are without side-effects. This is a great example that this is a false notion. Please keep this in mind with Remdesivir. “Authorities” are trying so hard to make you believe HCQ is killing people but Remdesivir isn’t and is completely safe. All drugs have side-effects. It’s up to you and your practitioner to weigh the benefits vs the risks but for politicians to ban certain drugs over other drugs reeks of conflicts of interest – which in fact it is: https://madisonarealymesupportgroup.com/2020/04/26/cdc-playbook-learning-from-lyme/